Folgen
ELISA BALDELLI
ELISA BALDELLI
Research affiliate, George Mason University
Bestätigte E-Mail-Adresse bei gmu.edu
Titel
Zitiert von
Zitiert von
Jahr
The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients
J Hallin, LD Engstrom, L Hargis, A Calinisan, R Aranda, DM Briere, ...
Cancer discovery 10 (1), 54-71, 2020
10252020
Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors …
V Ludovini, F Bianconi, L Pistola, R Chiari, V Minotti, R Colella, D Giuffrida, ...
Journal of thoracic oncology 6 (4), 707-715, 2011
1932011
Multiclass HCV resistance to direct‐acting antiviral failure in real‐life patients advocates for tailored second‐line therapies
VC Di Maio, V Cento, I Lenci, M Aragri, P Rossi, S Barbaliscia, M Melis, ...
Liver international 37 (4), 514-528, 2017
1032017
Association of cytidine deaminase and xeroderma pigmentosum group D polymorphisms with response, toxicity, and survival in cisplatin/gemcitabine-treated advanced non-small cell …
V Ludovini, I Floriani, L Pistola, V Minotti, M Meacci, R Chiari, ...
Journal of thoracic oncology 6 (12), 2018-2026, 2011
692011
Reverse phase protein microarrays
E Baldelli, V Calvert, A Hodge, A VanMeter, EF Petricoin, M Pierobon
Molecular profiling: methods and protocols, 149-169, 2017
532017
Computational model of EGFR and IGF1R pathways in lung cancer: a systems biology approach for translational oncology
F Bianconi, E Baldelli, V Ludovini, L Crinò, A Flacco, P Valigi
Biotechnology advances 30 (1), 142-153, 2012
522012
The sustained induction of c-MYC drives nab-paclitaxel resistance in primary pancreatic ductal carcinoma cells
E Parasido, GS Avetian, A Naeem, G Graham, M Pishvaian, E Glasgow, ...
Molecular Cancer Research 17 (9), 1815-1827, 2019
512019
Optimization of patient selection for EGFR-TKIs in advanced non-small cell lung cancer by combined analysis of KRAS, PIK3CA, MET, and non-sensitizing EGFR mutations
V Ludovini, F Bianconi, L Pistola, V Minotti, R Chiari, R Colella, ...
Cancer chemotherapy and pharmacology 69, 1289-1299, 2012
472012
Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-Mutant Pancreatic Cancer
CM Goodwin, AM Waters, JE Klomp, S Javaid, KL Bryant, CA Stalnecker, ...
Cancer research 83 (1), 141-157, 2023
462023
Impact of upfront cellular enrichment by laser capture microdissection on protein and phosphoprotein drug target signaling activation measurements in human lung cancer …
E Baldelli, EB Haura, L Crinò, DW Cress, V Ludovini, MB Schabath, ...
PROTEOMICS–Clinical Applications 9 (9-10), 928-937, 2015
362015
Integrated multi-omics analyses on patient-derived CRC organoids highlight altered molecular pathways in colorectal cancer progression involving PTEN
M Codrich, E Dalla, C Mio, G Antoniali, MC Malfatti, S Marzinotto, ...
Journal of Experimental & Clinical Cancer Research 40, 1-17, 2021
352021
Functional characterization of epithelial ovarian cancer histotypes by drug target based protein signaling activation mapping: implications for personalized cancer therapy
MI Sereni, E Baldelli, G Gambara, J Deng, L Zanotti, E Bandiera, ...
Proteomics 15 (2-3), 365-373, 2015
332015
Functional signaling pathway analysis of lung adenocarcinomas identifies novel therapeutic targets for KRAS mutant tumors
E Baldelli, G Bellezza, EB Haura, L Crinó, WD Cress, J Deng, V Ludovini, ...
Oncotarget 6 (32), 32368, 2015
292015
Proteogenomic analysis of lung adenocarcinoma reveals tumor heterogeneity, survival determinants, and therapeutically relevant pathways
AR Soltis, NW Bateman, J Liu, T Nguyen, TJ Franks, X Zhang, CL Dalgard, ...
Cell reports Medicine 3 (11), 2022
282022
A pilot study exploring the molecular architecture of the tumor microenvironment in human prostate cancer using laser capture microdissection and reverse phase protein microarray
E Pin, S Stratton, C Belluco, L Liotta, R Nagle, KA Hodge, J Deng, T Dong, ...
Molecular Oncology 10 (10), 1585-1594, 2016
262016
Concomitant high gene copy number and protein overexpression of IGF1R and EGFR negatively affect disease-free survival of surgically resected non-small-cell-lung cancer patients
V Ludovini, A Flacco, F Bianconi, M Ragusa, J Vannucci, G Bellezza, ...
Cancer chemotherapy and pharmacology 71 (3), 671-680, 2013
242013
CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment
JE Klomp, YS Lee, CM Goodwin, B Papke, JA Klomp, AM Waters, ...
Cell reports 37 (9), 2021
212021
The KRAS-regulated kinome identifies WEE1 and ERK coinhibition as a potential therapeutic strategy in KRAS-mutant pancreatic cancer
JN Diehl, JE Klomp, KR Snare, PS Hibshman, DR Blake, ZD Kaiser, ...
Journal of Biological Chemistry 297 (5), 2021
182021
Conditional robustness analysis for fragility discovery and target identification in biochemical networks and in cancer systems biology
F Bianconi, E Baldelli, V Luovini, EF Petricoin, L Crinò, P Valigi
BMC systems biology 9, 1-18, 2015
182015
AKT/mTOR signaling modulates resistance to endocrine therapy and CDK4/6 inhibition in metastatic breast cancers
MM Abu-Khalaf, K Alex Hodge, C Hatzis, E Baldelli, E El Gazzah, ...
NPJ Precision Oncology 7 (1), 18, 2023
162023
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20